Showing results (171-180 of 331) with videos related to
Sort By:
Pageof 34
Journal of Cancer Research and Clinical Oncology|May 17, 2023
Sclerosing mesenteritis following immune checkpoint inhibitor therapyAndrew G Kuang, Gabriel Sperling, Tom Z Liang, et al.The Lancet. Oncology|November 17, 2018
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyJoe-Elie Salem, Ali Manouchehri, Melissa Moey, et al.Journal for Immunotherapy of Cancer|January 21, 2022
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapyYing Jing, Xue Chen, Kunyan Li, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I ExpressionBala Theivanthiran, Nagendra Yarla, Kaylee Villareal, et al.Autoimmunity Reviews|June 15, 2020
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicitiesYves Allenbach, Céline Anquetil, Ali Manouchehri, et al.The Oncologist|August 14, 2021
Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer CenterNeha M Jain, Lauren Schmalz, Christopher Cann, et al.European Journal of Cancer (Oxford, England : 1990)|June 30, 2020
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligandJames Randall Patrinely, Arissa C Young, Henry Quach, et al.Nature Medicine|April 27, 2023
Multi-organ landscape of therapy-resistant melanomaSixue Liu, Prashanthi Dharanipragada, Shirley H Lomeli, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 29, 2020
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsMaria E Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, et al.Clinical Hematology International|November 25, 2021
High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell TherapyJiun-Ruey Hu, Ameet Patel, Shi Huang, et al.Pageof 34